Infectious Disease

Novavax’s updated Covid-19 vaccine receives FDA emergency use authorisation

Novavax has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its updated Covid-19 vaccine for individuals aged 12 years and over.

Moderna’s RSV vaccine mRESVIA gains EC approval

The European Commission (EC) has granted marketing authorisation for Moderna's mRESVIA (mRNA-1345) vaccine, designed for protecting individuals aged 60 and above from lower respiratory tract disease which is caused by RSV infection.

EMA CHMP recommends marketing authorisation for Moderna’s RSV vaccine

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorisation for Moderna's mRESVIA (mRNA-1345) vaccine for adults aged 60 and above.

FDA approves ViiV Healthcare’s Dovato for adolescent HIV treatment

The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Dovato (dolutegravir/lamivudine) to treat HIV-1 infection in adolescents.

Bavarian Nordic announces commercial availability of mpox vaccine in US

Bavarian Nordic has announced the commercial availability of JYNNEOS, which is claimed to be the only FDA-approved vaccine for mpox, in the US.

FDA approves Gilead’s Vemlidy sNDA for paediatric HBV patients

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences’ supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets to treat chronic hepatitis B virus (HBV) in paediatric patients.

Baseimmune secures funding for vaccine development

Baseimmune, a biotech firm specialising in artificial intelligence (AI)-driven vaccine development, has announced the successful closure of a £9m Series A funding round.

Exicure and Bluejay sign hepatitis treatment development deal

Exicure and Bluejay Therapeutics have reached a patent licencing agreement for the development of cavrotolimod as a potential hepatitis treatment.

Novartis acquires Chinook Therapeutics for $3.5bn upfront

Novartis has acquired US-based clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5bn upfront.